Table 2.

Multivariate analysis of treatment related mortality, relapse, treatment failure (1-LFS) and overall mortality for AML and MDS by cytogenetic groups and adjusted for significant covariates.

AML	N	Relative Risk	P-value	MDS	N	Relative Risk	P-value
TRM				TRM
Normal	641	1.00a	<0.411	Normal	237	1.00a	< 0.0011
MK positive	238	1.01 (0.74–1.39)	0.94	MK positive	219	1.80 (1.27–2.54)	< 0.001
Other unfavorable	1133	0.95 (0.77–1.18)	0.66	Other unfavorable	416	1.37 (0.99–1.90)	0.06
Intermediate	1568	0.86 (0.70–1.06)	0.16	Intermediate	606	1.01 (0.73–1.39)	0.97
				Favorable	97	0.95 (0.59–1.52)	0.83
Relapse				Relapse
Normal	641	1.00a	< 0.0011	Normal	237	1.00a	< 0.0011
MK positive	238	1.98 (1.58–2.49)	< 0.001	MK positive	219	2.39 (1.74–3.29)	< 0.001
Other unfavorable	1133	1.36 (1.14–1.63)	< 0.001	Other unfavorable	416	1.50 (1.11–2.04)	0.009
Intermediate	1568	0.90 (0.75–1.08)	0.27	Intermediate	606	1.12 (0.84–1.51)	0.44
				Favorable	97	1.19 (0.76–1.86)	0.44
Treatment Failure:				Treatment Failure:
Normal	641	1.00a	< 0.0011	Normal	237	1.00a	< 0.0011
MK positive	238	1.55 (1.29–1.86)	< 0.001	MK positive	219	2.17 (1.72–2.74)	< 0.001
Other unfavorable	1133	1.19 (1.04–1.37)	0.01	Other unfavorable	416	1.52 (1.22–1.89)	< 0.001
Intermediate	1568	0.88 (0.77–1.02)	0.09	Intermediate	606	1.13 (0.92–1.40)	0.25
				Favorable	97	1.15 (0.84–1.57)	0.40
Overall Mortality:				Overall Mortality:
Normal	643	1.00a	< 0.0011	Normal	241	1.00a	< 0.0011
MK positive	240	1.67 (1.38–2.01)	< 0.001	MK positive	221	2.02 (1.59–2.59)	< 0.001
Other unfavorable	1138	1.22 (1.06–1.40)	0.006	Other unfavorable	423	1.39 (1.10–1.77)	0.006
Intermediate	1579	0.90 (0.78–1.05)	0.17	Intermediate	611	0.96 (0.76–1.22)	0.73
				Favorable	98	1.00 (0.71–1.41)	1.00

¹Overall P value

^aReference group

Abbreviations: AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; MK, monosomal karyotype; TRM, transplant related mortality